Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enzalutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 18/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 1.00 |
| ▸ | GABRD | O14764 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | KLK3 | P07288 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 1/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 1/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 1/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 1/20 | 1.00 |
| ▸ | GABRE | P78334 | 1/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enzalutamide SCHEMBL29352764 | 1.00 | AR (1.00) | ARGABRPGABRDNR1I2NR3C1 | |
| Enzalutamide SCHEMBL16586461 | 0.96 | AR (0.92) | ARGABRPGABRDNR1I2NR3C1 | |
| Deutenzalutamide SCHEMBL29692768 | 0.94 | AR (0.89) | ARGABRPGABRDNR1I2NR3C1 | |
| Deutenzalutamide SCHEMBL18789402 | 0.94 | AR (0.89) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL15321260 | 0.93 | AR (0.87) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL15325679 | 0.93 | AR (0.87) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL21788386 | 0.93 | AR (0.87) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL23378228 | 0.92 | AR (0.85) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL15325749 | 0.92 | AR (0.84) | ARGABRPGABRDNR1I2NR3C1 | |
| SCHEMBL581352 | 0.91 | AR (0.84) | ARGABRPGABRDNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 910 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50642-E1 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2025-10-21 | — | — | US | claimed |
| EP-4363405-B1 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | QUIM SINTETICA S A (ES) | 2025-05-21 | — | — | EP | claimed |
| US-20240383861-A1 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | Química Sintética, S.A. (ES) | 2024-11-21 | — | — | US | claimed |
| EP-4112603-A1 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | Química Sintética, S.A. (ES) | 2023-01-04 | — | — | EP | claimed |
| US-RE49353-E1 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | ARAGON PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | claimed |
| EP-2785349-B2 | COMBINATION TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2022-11-09 | — | — | EP | claimed |
| US-11344499-B2 | Nanoparticles as delivery vehicles of active ingredients and methods for the production thereof | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2022-05-31 | — | — | US | claimed |
| US-20220160695-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | claimed |
| WO-2022063437-A1 | COMPOSITIONS FOR THE TREATMENT OF SALIVARY GLAND CARCINOMA | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | claimed |
| EP-3917519-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2021-12-08 | — | — | EP | claimed |
| US-9365510-B2 | Aziridine bisphenol ethers and related compounds and methods for their use | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2016-06-14 | — | — | US | claimed |
| US-20160022606-A1 | NOVEL THERAPY FOR PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | claimed |
| EP-2968219-A1 | NOVEL THERAPY FOR PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| EP-2900224-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | Aragon Pharmaceuticals, Inc. (US) | 2015-08-05 | — | — | EP | claimed |
| WO-2015112909-A1 | METHODS OF USING ANTI-STEAP1 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2015-07-30 | — | — | WO | claimed |
| WO-2015042170-A1 | COMPOSITIONS AND USES OF COMBINATIONS OF DIM-RELATED INDOLES AND SELECTED ANTI-ANDROGEN COMPOUNDS | WAYNE STATE UNIVERSITY (US) | 2015-03-26 | — | — | WO | claimed |
| WO-2015042029-A1 | COMBINATION DRUG THERAPY | GLAXOSMITHKLINE LLC (US) | 2015-03-26 | — | — | WO | claimed |
| WO-2014167428-A2 | AMORPHOUS 4-(3-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-5,5-DIMETHYL-4-OXO-2-THIOXOIMIDAZOLIDIN-1-YL)-2-FLUORO-N-METHYLBENZAMIDE | SHILPA MEDICARE LIMITED (IN) | 2014-10-16 | — | — | WO | claimed |
| WO-2014158875-A1 | NOVEL THERAPY FOR PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140088129-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | ARAGON PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088129-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | AR, SHBG, KLK3 | AR 1/4885GABRP 2633/4885GABRD 2171/4885 |
| US-20160022606-A1 | NOVEL THERAPY FOR PROSTATE CARCINOMA | CYP17A1, HSD17B1, HSD17B11 | AR 32/4885GABRP 3535/4885GABRD 2857/4885 |
| US-20220160695-A1 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | AR, KLK3, SHBG | AR 1/4885GABRP 2533/4885GABRD 2822/4885 |
| US-20240383861-A1 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | NR5A1, CYP19A1, SHBG | AR 6/4885GABRP 1477/4885GABRD 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.